Lilia Martinez de la Maza

Dr. Lilia Martinez de la Maza

Karolinska Insitutet, Stockholm
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Journal Of Hypertension
Verified
Journal Article
Closed access
RARocío Acuña
Rocío Acuña
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
JPJosé Ponce-Coria
José Ponce-Coria
NVNorma Vázquez
Norma Vázquez
POPenélope Ortal-Vite
Penélope Ortal-Vite
GGGerardo Gamba
Gerardo Gamba
Objectives Screening for variants in SLC12A1 and SLC12A3 genes, encoding the renal Na+:Cl− (NCC) and Na+:K+:2Cl− (NKCC2) cotransporters, respectively, in 3125 members of the Framingham Heart Study (FHS) revealed that carrying a rare mutation in one of these genes was associated with a significant reduction in blood pressure, in the risk of arterial hypertension, and of death due to cardiovascular disease. Because near 60% of the rare mutations identified have not been related to Bartter's or Gitelman's disease, the consequence of such mutations on cotransporter activity is unknown. Methods We used the heterologous expression system of Xenopus laevis oocytes, microinjected with wild-type or mutant NCC or NKCC2 cRNAs, to examine the effect of these inferred NCC and NKCC2 mutations on the cotransporters' functional properties. Cotransporter activity was defined as the diuretic-sensitive radioactive tracer uptake and response to known modulators was assessed. Results Basal NCC activity was significantly reduced in all NCC mutants and, excluding NCC-S186F, response to WNK3, WNK4, or intracellular chloride depletion was conserved. Similarly, basal activity was reduced in six out of nine NKCC2 mutants and response to WNK3 was maintained. No effect on protein expression was seen, except for NCC-S186F, which was significantly reduced. Conclusions The rare NCC or NKCC2 mutations found in the FHS significantly reduced the basal activity of the cotransporters. This observation supports that even a small, but chronic reduction of NCC or NKCC2 function results in a lower blood pressure and decreased risk of hypertension in otherwise healthy individuals in the general population.

1 November 2005 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
Jazmin Marlen Pérez RojasJazmin Marlen Pérez Rojas
Jazmin Marlen Pérez Rojas
SDStephanie Derive
Stephanie Derive
JBJorge A. Blanco
Jorge A. Blanco
CCCristino Cruz
Cristino Cruz
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
NBNorma A. Bobadilla
Norma A. Bobadilla
We showed that spironolactone reduced structural damage and prevented renal dysfunction in chronic cyclosporine (CsA) nephrotoxicity. These findings evidenced an aldosterone renal vascular effect under this condition. To investigate aldosterone’s role in modulating renal vascular tone, renocortical vasoactive pathways mRNA levels in chronic CsA nephrotoxicity as well as spironolactone’s effect on renal function in acute CsA nephrotoxicity were evaluated. Two experimental sets were designed. For chronic nephrotoxicity, rats fed with low-sodium diet were divided into groups receiving vehicle, spironolactone (Sp), CsA, and CsA+Sp, for 21 days. Creatinine clearance, survival percentage, and renocortical mRNA levels of pro-renin, angiotensinogen (Ang), angiotensin receptors (AT1A, AT1B, and AT2), preproendothelin, endothelin receptors (ETA, ETB), cyclooxygenase-2 (COX-2), and adenosine receptors (Ad1, Ad2A, Ad2B, and Ad3) were analyzed. For acute nephrotoxicity, similar groups fed with a standard chow diet for 7 days were included. Serum potassium and sodium, glomerular filtration rate (GFR), and renal blood flow (RBF) were determined. In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT1A, AT1B, ETB, and COX-2 mRNA levels. Spironolactone protective effect in chronic nephrotoxicity was associated with prevention of pro-renin upregulation and increased AT2, together with ETBreduction. In acute nephrotoxicity, spironolactone completely prevented GFR and RBF reduction induced by CsA. Our results suggest that aldosterone contributes to renal vasoconstriction observed in CsA nephrotoxicity and that renoprotection conferred by spironolactone was related to modification of renocortical vasoactive pathways expression, in which pro-renin normalization was the most evident change in chronic nephropathy. Finally, our data point to spironolactone as a potential treatment to reduce CsA nephrotoxicity in transplant patients.

23 July 2024 in Liver Transplantation
Verified
Journal Article
Open access
EBEmil Bluhme
Emil Bluhme
MGMarkus Gäbel
Markus Gäbel
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
VNVera Nilsén
Vera Nilsén
KHKarin Hildebrand
Karin Hildebrand
CJCarl Jorns
Carl Jorns
Liver transplantation using donors after controlled circulatory death (cDCD) is associated with poorer graft survival and increased incidence of non-anastomotic biliary strictures (NAS) compared to livers procured from brain dead donors (DBD). The use of Normothermic regional perfusion (NRP) during cDCD procurement may improve post-transplant outcome and reduce the incidence of NAS. In Sweden cDCD liver transplantation was introduced through a national pilot protocol with mandatory NRP. This study aims to evaluate the outcome of cDCD liver transplantation during the pilot period. Donor and recipient data were collected on all cDCD liver transplants during the pilot period between 2020 – December 2022. Outcome on NAS, patient- and graft survival, early allograft dysfunction, acute kidney injury, and comprehensive complication index was compared to a matched cohort of 28 patients transplanted with a DBD liver between 2018-2022. 18 patients were transplanted with a liver from a cDCD donor after using NRP. Mean functional warm ischemia time was 29±6 minutes. Mean lactate reduction during NRP was 8.7±2.4 mmol/L, end NRP perfusate ALT was 1.4±1 µkat/L. When comparing cDCD liver transplant recipients to DBD, no significant differences were observed in the incidence of NAS, patient and graft survival, comprehensive complication index, early allograft dysfunction, nor acute kidney injury. Study protocol MRCP in cDCD patients showed no signs of subclinical biliary strictures. Evaluation of the Swedish national pilot of cDCD liver transplantation with mandatory NRP shows comparable outcomes to a matched DBD cohort with 94.4 one-year patient and graft survival and no incidence of NAS within the first year. Export

Verified
Journal Article
Open access
PDF file
AHAmelia Hessheimer
Amelia Hessheimer
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
FSFarah Adel Al Shwely
Farah Adel Al Shwely
AEArlena Sofía Espinoza
Arlena Sofía Espinoza
FAFabio Ausania
Fabio Ausania
CFConstantino Fondevila
Constantino Fondevila
“Small-for-size” livers arising in the context of liver resection and transplantation are vulnerable to the effects of increased portal flow in the immediate postoperative period. Increased portal flow is an essential stimulus for liver regeneration. If the rise in flow and stimulus for regeneration are excessive; however, liver failure and patient death may result. Somatostatin is an endogenous peptide hormone that may be administered exogenously to not only reduce portal blood flow but also offer direct protection to different cells in the liver. In this review article, we describe key changes that transpire in the liver following a relative size reduction occurring in the context of resection and transplantation and the largely beneficial effects that peri-operative somatostatin therapy may help achieve in this setting.

28 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
VPVerónica Prado
Verónica Prado
AHAmelia J. Hessheimer
Amelia J. Hessheimer
JMJavier Muñoz
Javier Muñoz
JGJuan Carlos García-Valdecasas
Juan Carlos García-Valdecasas
CFConstantino Fondevila
Constantino Fondevila
A primary limitation in hepatic surgery is leaving a remnant liver of adequate size and function. Experimental models have been designed to study processes of liver injury and regeneration in this context, yet a formula to accurately calculate liver mass in an animal model is lacking. This study aims to create a novel and simple formula to estimate the mass of the native liver in a species of pigs commonly used in experimental liver surgery protocols. Using data from 200 male weanling Landrace-Large White hybrid pigs, multiple linear regression analysis is used to generate the formula. Clinical features used as variables for the predictive model are body mass and length. The final formula for pig liver mass is as follows: Liver mass (g) = 26.34232 * Body mass (kg) – 1.270629 * Length (cm) + 163.0076; R2 = 0.7307. This formula for porcine liver mass is simple to use and may be helpful in studies using animals of similar characteristics to evaluate restoration of liver mass following major hepatectomy.

1 September 2018 in HPB
Verified
Journal Article
Closed access
JCJordi Camps
Jordi Camps
MPM. Paraira
M. Paraira
EHE. Herrero
E. Herrero
MGM.I. García
M.I. García
LMLilia Martinez de la Maza
Lilia Martinez de la Maza
ECE. Cugat
E. Cugat